Hepatocellular carcinoma (HCC) constitutes the 5th most frequent cancer worldwide, and
due to a lack of treatment options, HCC represents the 3rd most lethal cancer worldwide …

The approval of sorafenib as the standard of care (SOC) for advanced hepatocellular
carcinoma (HCC) fostered interest to further evaluate several other targeted therapies and …

Advances in molecular cell biology over the last decade have clarified the mechanisms
involved in cancer growth, invasion, and metastasis, and enabled the development of …

In recent years, molecular-targeted agents have been used clinically to treat various
malignant tumors. In May 2009, sorafenib (Nexavar®) was approved in Japan for …

Hepatocellular carcinoma (HCC) is a common cancer with poor prognosis and worldwide
rising incidence during the last years. Although orthotopic liver transplantation, surgical …

Abstract According to the International Agency for Research on Cancer, approximately
670,000 new cases of hepatocellular carcinoma (HCC) developed in 2005, making it the fifth …

It is well appreciated that hepatocellular carcinoma (HCC) represents one of the most
challenging malignancies of worldwide importance. In fact, HCC is the fifth most common …

Cancer treatment has been revolutionized by the advent of new molecular targeted and
immunotherapeutic agents. Identification of the role of tumor angiogenesis changed the …

Since sorafenib, a multikinase inhibitor targeting angiogenesis of hepatocellular carcinoma
(HCC), demonstrated survival benefits in recent clinical trials, it has changed the treatment …

Hepatocellular carcinoma (HCC) can be lethal due to its aggressive course and lack of
effective systemic therapies for advanced disease. Sorafenib is the only systemic therapy …